Mutated Pseudomonas Exotoxins with Reduced Antigenicity
Description of Invention:
The use of Pseudomonas exotoxins (PE) for treatment of solid tumors, in particular, has been limited because of the development of neutralizing antibodies to the immunotoxin after the first administration. These antibodies develop before most protocols would call for a second administration of the immunotoxin, and therefore render further use of the immunotoxins ineffective against solid tumors in previously exposed patients.
The studies underlying this novel invention reveal that the predominant immune response of patients to PE-immunotoxins is the PE portion of the immunotoxin. This finding indicates that reducing the antigenicity of the PE molecules used for immunotoxins would reduce the overall antigenicity of the immunotoxin, and increase their utility.
Therefore, this invention relates to mutated Pseudomonas exotoxins (PE) that have reduced antigenicity compared to PEs containing the native sequence. The PEs of this invention have one or more individual mutations that reduce antibody binding to one or more epitopes of PE.
Inventors:
Ira H. Pastan et al. (NCI)
Patent Status:
DHHS Reference No. E-262-2005/0 --
U.S. Provisional Application No. 60/703,798 filed 29 Jul 2005
PCT Application No. PCT/US2006/028986 filed 25 Jul 2006, which published as WO 2007/016150 on 08 Feb 2007 Licensing Status:
In addition to licensing, the technology is available for further development through collaborative research opportunities with the inventors.
Portfolios: Cancer
Cancer -Therapeutics-Immunoconjugates Cancer -Therapeutics
For Additional Information Please Contact: David A. Lambertson Ph.D.
NIH Office of Technology Transfer
6011 Executive Blvd, Suite 325
Rockville, MD 20852-3804
Phone: (301)435-4632
Email: lambertsond@mail.nih.gov
Fax: (301) 402-0220
